Core Insights - Lanwei Medical (301060.SZ) reported a total operating revenue of 351 million yuan for Q1 2025, a decrease of 85.56 million yuan compared to the same period last year, representing a year-on-year decline of 19.60% [1] - The net profit attributable to shareholders was -8.08 million yuan, ranking 24th among disclosed peers, a decrease of 9.15 million yuan compared to the same period last year, reflecting a year-on-year decline of 854.01% [1] - The net cash inflow from operating activities was 1.66 million yuan, ranking 18th among disclosed peers [1] Financial Ratios - The latest debt-to-asset ratio is 30.74%, ranking 22nd among disclosed peers, with an increase of 0.13 percentage points from the previous quarter [3] - The latest gross profit margin is 19.95%, ranking 29th among disclosed peers, a decrease of 2.13 percentage points from the previous quarter and a decrease of 1.95 percentage points year-on-year [3] - The latest return on equity (ROE) is -0.49%, ranking 25th among disclosed peers, a decrease of 0.55 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.02 yuan, ranking 25th among disclosed peers, a decrease of 0.02 yuan compared to the same period last year, reflecting a year-on-year decline of 851.85% [3] - The latest total asset turnover ratio is 0.13 times, a decrease of 0.01 times year-on-year, representing a decline of 9.77% [3] - The latest inventory turnover ratio is 0.83 times, ranking 19th among disclosed peers, a decrease of 0.14 times year-on-year, reflecting a decline of 14.43% [3] Shareholder Structure - The number of shareholders is 24,100, with the top ten shareholders holding 254 million shares, accounting for 63.54% of the total share capital [3] - The largest shareholder is Shanghai Lanwei Investment Co., Ltd., holding 37.34% [3] - Other notable shareholders include Zeng Weixiong (13.42%) and Hai Lan Group Co., Ltd. (3.82%) [3]
兰卫医学(301060.SZ)2025年一季报净利润为-808.09万元，同比由盈转亏